Navigation Links
Extra Drug Improves Rectal Cancer Treatment
Date:4/15/2008

And contraceptive drug helps kill cervical cancer cells missed by chemotherapy

TUESDAY, April 15 (HealthDay News) -- Adding the cancer drug Avastin to radiation and chemotherapy improves results for patients with rectal cancer.

And adding the contraceptive drug mifepristone (RU-486, the so-called abortion pill) to chemotherapy kills ovarian cancer cells that escaped cisplatin treatment.

Those are the conclusions of two reports on new trends in cancer drugs presented Tuesday at the American Association for Cancer Research annual meeting, in San Diego.

In the first study, researchers found that adding Avastin to chemotherapy and radiation improved three-year, disease-free survival by 91 percent among patients with rectal cancer.

"Avastin is an antibody against a potent angiogenic molecule known as vascular endothelial growth factor (VEGF) and has been approved to treat several types of cancers," Rakesh K. Jain, director of the Edwin L. Steele Laboratory for Tumor Biology at Massachusetts General Hospital, said during a teleconference. In essence, VEGF promotes the growth of blood vessels in cancer tumors, he said.

According to the U.S. National Cancer Institute, there are more than 40,000 new cases of rectal cancer diagnosed each year in the United States.

The goal of Jain's team's research was to find ways to make standard chemotherapy more effective. For the study, 25 patients with rectal cancer were treated with Avastin, along with chemotherapy and external beam radiation and surgery. The addition of Avastin increased the density of blood vessels in the tumor and repaired tumor vessels damaged by chemotherapy or radiation, he said.

"Avastin leads to vessel normalization, it repairs vessels," Jain said. "By repairing the vessels, it makes the tumor better-nourished so the drugs can get there and work better," he said. "That's a very counterintuitive finding."

Avastin alone, or in combination with other treatments, increased levels of the factors VEGF, PlGF and SDF1 alpha, the researchers reported. Patients with higher levels of VEGF and PlGF after Avastin responded better to chemotherapy and radiation, Jain said.

The increase in SDF1 alpha suggests that this factor could be a new drug target to extend the life of patients after other therapies have failed, Jain said. "This is a new drug candidate," he said.

Among the patients receiving Avastin, local control of their disease reached 100 percent, Jain said. "Three-year, progression-free survival was 91 percent," he said.

Jain cautioned, however, that these results were very preliminary and needed to be confirmed.

In the second study, researchers found that using mifepristone along with the chemotherapy drug cisplatin might improve success in treating ovarian cancer.

"Mifepristone, which was initially created for contraceptive purposes, has a therapeutic effect against ovarian cancers that remained after standard cisplatin therapy," lead researcher Dr. Carlos M. Telleria, an assistant professor of medicine at the University of South Dakota Sanford School of Medicine, said during Tuesday's teleconference.

One of the main problems in treating ovarian cancer is that the usual treatment with the chemotherapy drug cisplatin doesn't kill all the cancer cells. This allows the cells to reform into colonies and the cancer to continue to grow.

"We show for the first time that mifepristone is effective in preventing the re-growth of ovarian cancer cells that survive standard cisplatin chemotherapy," Telleria said.

There are more than 20,000 women diagnosed with ovarian cancer every year in the United States, and more than 15,000 women die from the disease annually, Telleria noted.

In the study, the researchers exposed ovarian cancer cells to cisplatin. Although cisplatin killed the majority of the cells, there were cells that escaped and regrouped as cancer. This happened all three times the cells were treated with cisplatin over 36 days.

However, when cells were treated with cisplatin and then exposed to mifepristone, none of the cancer cells survived, the researchers found.

"This study suggests that mifepristone has the potential to improve the success of the standard platinum drugs in the treatment of ovarian cancer," Telleria said.

More information

For more on cancer, visit the American Cancer Society.



SOURCES: April 15, 2008, teleconference with Rakesh K. Jain, Ph.D., director, Edwin L. Steele Laboratory for Tumor Biology, Massachusetts General Hospital, Boston; Carlos M. Telleria, M.D., assistant professor of medicine, University of South Dakota Sanford School of Medicine, Vermillion; American Association for Cancer Research annual meeting, San Diego


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Green Tea, Mushroom Extract Combo Slows Sarcomas
2. Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma
3. Crannose(TM) Extra Strength Womens Health Formula Targets Urinary Tract Infections
4. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
5. Apple pectin, apple juice extracts shown to have anticarcinogenic effects on colon
6. Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer
7. Independent Survey Names CyberKnife(R) System Most Widely Used Extracranial Radiosurgery Technology
8. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
9. GetWellNetwork Partners with DAISY Foundation to Recognize Extraordinary Nurses
10. Broccoli Sprout Extract Hinders Bladder Cancer Development
11. Do todays young people really think they are so extraordinary?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
Breaking Medicine Technology: